171 related articles for article (PubMed ID: 18765557)
1. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.
Haining WN; Davies J; Kanzler H; Drury L; Brenn T; Evans J; Angelosanto J; Rivoli S; Russell K; George S; Sims P; Neuberg D; Li X; Kutok J; Morgan J; Wen P; Demetri G; Coffman RL; Nadler LM
Clin Cancer Res; 2008 Sep; 14(17):5626-34. PubMed ID: 18765557
[TBL] [Abstract][Full Text] [Related]
2. CpG-independent synergistic induction of beta-chemokines and a dendritic cell phenotype by orthophosphorothioate oligodeoxynucleotides and granulocyte-macrophage colony-stimulating factor in elutriated human primary monocytes.
Wang J; Alvarez R; Roderiquez G; Guan E; Caldwell Q; Wang J; Phelan M; Norcross MA
J Immunol; 2005 May; 174(10):6113-21. PubMed ID: 15879106
[TBL] [Abstract][Full Text] [Related]
3. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
[TBL] [Abstract][Full Text] [Related]
5. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.
Krug A; Towarowski A; Britsch S; Rothenfusser S; Hornung V; Bals R; Giese T; Engelmann H; Endres S; Krieg AM; Hartmann G
Eur J Immunol; 2001 Oct; 31(10):3026-37. PubMed ID: 11592079
[TBL] [Abstract][Full Text] [Related]
7. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
8. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.
Krug A; Rothenfusser S; Hornung V; Jahrsdörfer B; Blackwell S; Ballas ZK; Endres S; Krieg AM; Hartmann G
Eur J Immunol; 2001 Jul; 31(7):2154-63. PubMed ID: 11449369
[TBL] [Abstract][Full Text] [Related]
9. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells.
Krug A; Rothenfusser S; Selinger S; Bock C; Kerkmann M; Battiany J; Sarris A; Giese T; Speiser D; Endres S; Hartmann G
J Immunol; 2003 Apr; 170(7):3468-77. PubMed ID: 12646607
[TBL] [Abstract][Full Text] [Related]
10. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
Ali OA; Verbeke C; Johnson C; Sands RW; Lewin SA; White D; Doherty E; Dranoff G; Mooney DJ
Cancer Res; 2014 Mar; 74(6):1670-81. PubMed ID: 24480625
[TBL] [Abstract][Full Text] [Related]
11. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells.
Moseman EA; Liang X; Dawson AJ; Panoskaltsis-Mortari A; Krieg AM; Liu YJ; Blazar BR; Chen W
J Immunol; 2004 Oct; 173(7):4433-42. PubMed ID: 15383574
[TBL] [Abstract][Full Text] [Related]
12. [Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma].
Katsuda M; Iwahashi M; Matsuda K; Miyazawa M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1942-4. PubMed ID: 22202246
[TBL] [Abstract][Full Text] [Related]
13. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
Marschner A; Rothenfusser S; Hornung V; Prell D; Krug A; Kerkmann M; Wellisch D; Poeck H; Greinacher A; Giese T; Endres S; Hartmann G
Eur J Immunol; 2005 Aug; 35(8):2347-57. PubMed ID: 16025562
[TBL] [Abstract][Full Text] [Related]
14. Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides.
Kochenderfer JN; Chien CD; Simpson JL; Gress RE
Clin Immunol; 2007 Aug; 124(2):119-30. PubMed ID: 17584532
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
[TBL] [Abstract][Full Text] [Related]
16. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
17. CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells.
Teleshova N; Kenney J; Jones J; Marshall J; Van Nest G; Dufour J; Bohm R; Lifson JD; Gettie A; Pope M
J Immunol; 2004 Aug; 173(3):1647-57. PubMed ID: 15265893
[TBL] [Abstract][Full Text] [Related]
18. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
Front Immunol; 2021; 12():803090. PubMed ID: 35003132
[TBL] [Abstract][Full Text] [Related]
19. Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals.
Martinson JA; Tenorio AR; Montoya CJ; Al-Harthi L; Gichinga CN; Krieg AM; Baum LL; Landay AL
Immunology; 2007 Apr; 120(4):526-35. PubMed ID: 17343615
[TBL] [Abstract][Full Text] [Related]
20. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
